EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 15-Jul-2025 17:11 ET (15-Jul-2025 21:11 GMT/UTC)

Prostate cancer cells survive treatment by storing fat in low oxygen conditions

Impact Journals LLC
Peer-Reviewed Publication

BUFFALO, NY – July 14, 2025 – A new research paper was published in Volume 16 of Oncotarget on June 25, 2025, titled “Hypoxia induced lipid droplet accumulation promotes resistance to ferroptosis in prostate cancer.”

Journal: Oncotarget

Mayo Clinic researchers link CAR-T cell aging to cancer relapse

Mayo Clinic
Peer-Reviewed Publication

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy. Over time, the engineered immune cells age and lose their ability to fight cancer.

Journal: Molecular Cancer
Funder: Mayo Clinic Comprehensive Cancer Center, Eagles 5th District Cancer Telethon Funds for Cancer Research, State of Minnesota, Georgia and Michael Michelson

Bronchoscopic lung-biopsy techniques match percutaneous approaches for comprehensive biomarker testing with fewer complications, new guideline concludes

International Association for the Study of Lung Cancer
Peer-Reviewed Publication

A multidisciplinary guideline panel convened by the American Association of Bronchology and Interventional Pulmonology (AABIP) and the Early Detection & Screening Committee of the International Association for the Study of Lung Cancer (IASLC) has determined that guided-bronchoscopy sampling provides tissue of comparable adequacy for comprehensive biomarker testing to percutaneous (CT-guided) biopsy, while delivering a superior safety profile—especially when contemporary navigational technologies are employed

Journal: Journal of Thoracic Oncology

Viome and Scripps Research Partner to develop first at-home RNA screening test to prevent colon cancer before it strikes

Scripps Research Institute
Business Announcement

Viome Life Sciences, the leader in AI-powered, RNA-based diagnostics and precision nutrition and Scripps Research, the leader in accelerating the impact of fundamental research on human health, today announced a strategic partnership to develop and clinically validate the first at-home RNA test designed to detect precancerous colon polyps, enabling early prevention of colorectal cancer.

Landmark study in cell introduces first-of-its-kind optogenetic screening platform for drug discovery

Integrated Biosciences
Peer-Reviewed Publication

A landmark study published in Cell has unveiled a first-of-a-kind optogenetic screening platform, developed by scientists at Integrated Biosciences. The Cell paper demonstrates the platform’s capabilities by applying it to the integrated stress response (ISR), a key aging- and disease-associated signaling pathway implicated in neurodegeneration, cancer and viral infection.

Journal: Cell

ERC funding to understand tumor evolution to defeat cancer

Institute for Bioengineering of Catalonia (IBEC)
Grant and Award Announcement

Xavier Rovira, principal investigator at IBEC, has been awarded an ERC Proof of Concept Grant. These prestigious grants are awarded by the European Research Council to explore the commercial and social potential of research projects carried out at European institutions. Rovira's project seeks to develop the EVOaware platform, which is designed to address tumour resistance to therapies and accelerate the discovery and development of new cancer treatments.

Funder: European Research Council

Bar-Ilan University wins dual ERC grants for groundbreaking research in life sciences and AI policy analysis

Bar-Ilan University
Grant and Award Announcement

Two cutting-edge research projects at Bar-Ilan University have been awarded Proof of Concept (PoC) Grants from the European Research Council (ERC)—a major achievement that highlights the university’s interdisciplinary leadership in both biomedical science and AI-driven public policy.

New label-free imaging tracks cancer treatment in single cells

Helmholtz Munich (Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH))
Peer-Reviewed Publication

Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer treatment responses in individual cells – without the need for dyes or labels. Their mid-infrared optoacoustic microscopy (MiROM) technology enables real-time visualization of protein changes inside living myeloma cells, providing early insights into treatment effectiveness. By detecting protein misfolding, a key indicator of myeloma treatment response, MiROM offers a faster, more precise approach to personalizing therapy for multiple myeloma patients.

Journal: Nature Biomedical Engineering

Fighting leukemia by breaking a hidden cell loop

Medical University of South Carolina
Peer-Reviewed Publication

MUSC Hollings Cancer Center researchers have discovered a hidden feedback loop that helps leukemia cells survive and have developed a new immunotherapy that can break that loop. The loop is between a protein called IL-33 and its receptor IL1RL1, which together help acute myeloid leukemia cells grow and evade treatment. To disrupt this loop, the researchers created a bispecific antibody that both kills leukemia cells carrying IL1RL1 and activates immune cells that can fight off cancer. In lab and animal models, the therapy significantly slowed disease progression, reduced immune suppression and improved survival without major side effects. The research offers a potential new off-the-shelf treatment for leukemia and other cancers with similar tumor environments.

Journal: Nature Communications
Funder: NIH/National Cancer Institute, U.S. Department of Defense, NIH/National Cancer Institute

Singapore-developed cancer drug shows promise as treatment for blindness

Agency for Science, Technology and Research (A*STAR), Singapore
Peer-Reviewed Publication

Singapore researchers have discovered that a Singapore-developed cancer drug, originally developed at A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB), shows potential as a new treatment approach for two leading causes of blindness worldwide. In pre-clinical studies published in Nature Communications, PRL3-zumab effectively reduced leakage from damaged blood vessels—a major cause of vision loss—showing promise as a potential new treatment for patients whose conditions do not respond well to current therapies.

Journal: Nature Communications

1
2
3
4
5